Author (Year)	Groups Studied and Intervention	Results and Findings	Conclusions
Silberstein et al, 2020[@146612]	1072 participants. Mean age of 40.5 years. 88.2% female. 91.0% white.	Significant reduction in migraine days over treatment period. Reduction to severe headache-related life impact.	Effective reduction in number and severity of migraines over treatment period
Dodick et al., 2014[@146599]	174 patients aged 18-55 with 5-14 migraines per 28-day period.	Significant reduction in mean migraine days over weeks 5-8 in 1000mg group compared to baseline.	Significant reduction in migraine frequency compared to baseline. No significant adverse effects found for 1000mg eptinezumab group compared to placebo.
Ashina et al., 2020[@146601]	888 participants aged 18-75 with a diagnosis of migraine	Reduction in mean monthly migraines across all treatment groups. Evenly disbursed TAEA across groups.	Unchanged safety profile. Minimum dosage of 100mg.
Dodick et al., 2019[@146613]	616 men and women with a diagnosis of chronic migraine (CM). 300mg, 100mg, 30mg, and 10mg groups versus placebo.	Significantly reduced mean monthly migraine days (MMMDs) compared to placebo across all eptinezumab groups, with greatest benefit seen in 300mg group.	Equal TEAEs across all groups. No serious TEAEs attributed to eptinezumab. Effective reduction of migraines favoring high dosage groups & well tolerated.
Saper et al., 2018[@146614]	See Ashina et. Al., 2020	Reduction in mean monthly migraine days, including reduction in migraines one day after administration.	Significant reduction in number of migraines from baseline and compared to placebo group.